Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts discuss a pair of topics making headlines in recent weeks: the US Food and Drug Administration’s 510(k) clearance for the Accu-Chek Solo micropump system and Abbott’s acquisition of Bigfoot Biomedical.

In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.

Video version: https://www.hcplive.com/view/diabetes-dialogue-making-sense-of-semaglutide-in-type-1-diabetes 

Hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-tandem-mobi-and-welldoc-bluestar-platform

Hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes.

Video version: https://www.hcplive.com/view/diabetes-dialogue-addressing-health-disparities-with-diabetes-technology-with-etty-vider-pharmd 

In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes. The 4 diabetes agents included on the list, which were empagliflozin, dapagliflozin, sitagliptin, and Novo Nordisk-branded insulin products, accounted for more than $16 billion in Part D spending in 2022.

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.

Video version: https://www.hcplive.com/view/diabetes-dialogue-the-role-of-nutrition-in-diabetes-management-with-dawn-noe-rdn-ld

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

Video version: https://www.hcplive.com/view/diabetes-dialogue-implications-of-select-trial-and-brenzavvy-on-cost-plus-drugs

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th-anniversary celebration.

Video version: https://www.hcplive.com/view/diabetes-dialogue-adces-2023-recap

After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.

Video version: https://www.hcplive.com/view/diabetes-dialogue-ada-2023-recap

Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.

Video version: https://www.hcplive.com/view/diabetes-dialogue-latest-news-in-insulin-delivery-with-gary-scheiner-ms

David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.

Video version: https://www.hcplive.com/view/diabetes-dialogue-embracing-social-media-as-a-clinician-with-david-ahn-md 

Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.

Video version: https://www.hcplive.com/view/diabetes-dialogue-establishing-time-in-range-as-a-primary-glucose-metric 

Investigators from the TRANSITION-T2D study join Diabetes Dialogue to discuss the study and implications for care.

Video version: https://www.hcplive.com/view/diabetes-dialogue-transition-t2d

W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics.

Video version: https://www.hcplive.com/view/diabetes-dialogue-second-generation-obesity-medications-with-w-timothy-garvey-md

Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.

Video version: https://www.hcplive.com/view/diabetes-dialogue-improving-implementation-of-new-technology-with-cari-berget-rn-mph

Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.

Video version: https://www.hcplive.com/view/diabetes-dialogue-managing-addressing-mental-health-needs-in-diabetes

At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.

Video version: https://www.hcplive.com/view/diabetes-dialogue-reforming-language-in-metabolic-disease-with-jane-dickinson-rn-phd 

At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.

Video version: https://www.hcplive.com/view/diabetes-dialogue-diabetic-foot-ulcers-and-social-determinants-of-health 

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

In this special edition episode, hosts sit down for an in-depth discussion surrounding the new management algorithms from the AACE and break down how they expect the new guidance to impact patient care.

In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.

A recap of the top news and research from the 16th annual meeting for Advanced Technologies and Treatments for Diabetes in Berlin, Germany.

In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.

In this episode, hosts are joined by Grazia Aleppo, MD, to discuss the development of guideline recommendations for diabetes technology as well as her top takeaways from the ATTD 2023 meeting.

In this episode, hosts are joined by Marissa Town, BSN, RN, and Renza Scibilia for a discussion centered around the role of the patient voice in diabetes management while on site at ATTD 2023.

In this episode, hosts are joined by the associate director of Medical Affairs and Medical Education at MannKind for a special edition episode from ATTD 23 that focuses on use of inhaled insulin and future research plans for MannKind.

In this episode, Irl Hirsch, MD, discusses a study he is conducting examining skin changes associated with insulin pump use in people with type 1 diabetes. Later in the episode, Hirsch discusses what he is most excited about in terms of ongoing and future research in diabetes management.

In this episode from ATTD 2023, hosts are joined by Joanne Rinker, MS, RDN, who provides perspective on hearing loss in diabetes, including prevalence, the need for screening, and the underrecognition of auditory issues in the midst of a growing population of people with diabetes.

In this episode, hosts sit down with Katharine Barnard-Kelly, PhD, at ATTD 2023 to discuss the evolving recognition of the role of psychology in diabetes management for both pediatric and adult populations.

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

Check out the video version here.

In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.

In the December 2022 episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

Hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP,  discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.